Skip to main content
Top

Familial Cancer

2001 - 2025
Volumes
102
Issues
Chevron right icon
Issue 1/2025
Latest issue

About this journal

Clinical cancer genetics has now matured to a truly multidisciplinary medical discipline in which clinical and molecular geneticists work with clinical and medical oncologists as well as with psycho-social workers.

Due to the multidisciplinary nature of clinical cancer genetics most papers are currently being published in a wide variety of journals on epidemiology, oncology and genetics. Familial Cancer provides a forum bringing these topics together, focusing on the interests and needs of the clinician.

The journal concentrates on clinical cancer genetics. Most major areas in the field are included, such as epidemiology of familial cancer, molecular analysis and diagnosis, clinical expression, treatment and prevention, counseling and the health economics of familial cancer.

Familial Cancer publishes Original Articles, Reviews, Short Communications, Book Reviews, and Letters to the Editor.

Metadata
Title
Familial Cancer
Coverage
Volume 1/2001 - Volume 24/2025
Publisher
Springer Netherlands
Electronic ISSN
1573-7292
Print ISSN
1389-9600
Journal ID
10689
DOI
https://doi.org/10.1007/10689.1573-7292

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now